8-K
filed July 14, 2023, 7:59 PM ET
ticker PMDI
CIK 0000806517
leadership
confidence high
sentiment neutral
materiality 0.70
Psychemedics CEO Raymond Kubacki to retire; Brian Hullinger named successor as President/CEO
PSYCHEMEDICS CORP
- Raymond Kubacki and director Fred Weinert retire effective Aug 17, 2023; controller William Norris resigns effective July 21.
- Brian Hullinger appointed President/CEO effective Aug 17; base salary $375,000, target bonus $190,000 (2023 guaranteed).
- Hullinger receives inducement option for 300,000 shares in three tranches: time-based and VWAP-linked targets.
- Michael Weisenhoff appointed principal financial/accounting manager (salary $135,000) effective July 20.
- Kubacki enters retirement agreement with consulting at $5,000/week; his 44,000 stock units fully vest on consulting end.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
William Norris resigned as Controller at PSYCHEMEDICS CORP.
- Action
- resigned
- Role
- Controller
Exact text from the filing
On July 12, 2023, William Norris, the Company’s Controller, resigned from such position, and otherwise as an officer of the Company, effective July 21, 2023 to take a position with a home healthcare technology company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Fred J. Weinert retired as director at PSYCHEMEDICS CORP.
- Action
- retired
- Role
- director
Exact text from the filing
On July 12, 2023, Fred J. Weinert, a director of the Company, notified the Company that he will retire as a director effective August 17, 2023 coincident with the Annual Meeting of Stockholders on such date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Raymond C. Kubacki retired as Chairman, Chief Executive Officer and President at PSYCHEMEDICS CORP.
- Action
- retired
- Role
- Chairman, Chief Executive Officer and President
Exact text from the filing
On July 12, 2023 Raymond C. Kubacki, the Company’s Chairman, Chief Executive Officer and President notified the Company that he will retire as Chairman Chief Executive Officer and President effective August 17, 2023 coincident with the Annual Meeting of Stockholders on such date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brian Hullinger was appointed as President and Chief Executive Officer at PSYCHEMEDICS CORP.
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
On July 12, 2023, the Company announced Brian Hullinger as the new President and Chief Executive Officer of the Company, to take effect on August 17, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Weisenhoff was appointed as principal financial and accounting manager at PSYCHEMEDICS CORP.
- Action
- appointed
- Role
- principal financial and accounting manager
Exact text from the filing
On July 13, 2023, the Company appointed Michael Weisenhoff, Assistant Controller of the Company, as the Company’s principal financial and accounting manager, to take effect as of July 20, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Brian Hullinger was appointed as director at PSYCHEMEDICS CORP.
- Action
- appointed
- Role
- director
Exact text from the filing
He has also been nominated to be elected as a director of the Company at the Annual Meeting of Stockholders to be held on August 17, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.